PT-141 Guide & Protocols

PT-141 is different from almost everything else on this site in one important way: it isn't a course you build up to, it's an as-needed dose taken before the moment it's for. Below is the on-demand pattern most commonly described, why cycling and stacking barely apply here, and how it compares to Melanotan II, the compound it was originally developed from.

Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target amount you're working with.

What it is

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that acts on melanocortin receptors in the brain, primarily MC3R and MC4R, rather than on the body directly the way most compounds on this site do. It's a metabolite of Melanotan II, an earlier melanocortin peptide, refined down to the pathway involved in sexual desire. It's the active ingredient in Vyleesi, the FDA-approved on-demand treatment for hypoactive sexual desire disorder in premenopausal women, and the version sold by research vendors is the same molecule outside pharmaceutical channels, not manufactured to the same standard, with purity and concentration accuracy varying by source.

What people use it for

Low sexual desire is the entire conversation here, and it's worth saying plainly: this is the one compound on this site with a real FDA approval behind exactly that use in women. The RECONNECT trials that led to approval measured self-reported desire and satisfying sexual events in premenopausal women, and that's the population and the outcome the evidence base actually supports.

Formulations

PT-141 ships as a lyophilized powder that needs reconstitution before use. Vendors most commonly sell 2 and 5 mg vials. The approved Vyleesi product ships differently, as a prefilled 1.75 mg autoinjector, which research vendors don't replicate.

Dosing protocols

PT-141 doesn't build up over weeks the way a GLP-1 or growth hormone compound does. What's described is a single on-demand amount, taken ahead of the moment it's for, not a weekly schedule that escalates toward a maintenance number.

See the PT-141 research notes for more background before reading the dosing itself.

Standard on-demand amount

The pattern most closely mirroring the approved trial protocol. Amount: 1 to 2 mg. Timing: roughly 45 minutes before anticipated activity, which is the window used in the RECONNECT trials. Frequency: the approved product's label caps use at one dose in 24 hours and no more than 8 doses in a month, a ceiling commonly referenced even by people using research-grade material outside that labeled protocol.

Lower amount, more frequent use

A less commonly used variant, without a trial behind it. A smaller amount, 0.5 to 1 mg, used more often than the on-demand pattern above. This isn't something the RECONNECT trials tested; it's a community variant aimed at avoiding the nausea and flushing that climb with amount, at the cost of moving away from the dosing the approval evidence actually covers.

Amount total, for planning your vial purchase: at the labeled ceiling of 8 doses a month at 1.75 mg each, that's 14 mg a month, or roughly 168 mg over a year. Most people use it well below that ceiling, since it's tied to actual occasions rather than a fixed schedule, so a single 5 mg vial commonly covers several uses before running out. Compare vendors on price per milligram against your own realistic frequency rather than the labeled maximum.

How much to reconstitute at once: this is the compound on this site where reconstituting too much at once is the easiest mistake to make, since a 28-day refrigerated window applies whether it's used once or eight times that month. Occasional, infrequent use is common here, so reconstituting the full 5 mg vial when a handful of uses a month is realistic risks discarding more than half of it once the window closes. Reconstituting a smaller 2 mg vial, or adding less bac water to a larger one so a smaller volume gets used up faster, matches the amount mixed to what a realistic month of on-demand use actually draws. See how much to reconstitute at once for the general math.

Cycling guidelines

Cycling in the on-then-off sense used elsewhere on this site doesn't really apply to PT-141. It's an as-needed compound, not a sustained course, so there's no maintenance phase to taper down from and no rest period to observe between uses beyond the 24-hour spacing already built into the labeled protocol.

Signs to stop using it and reconsider:

• Blood pressure that runs noticeably higher in the hours after a dose, particularly in anyone with existing high blood pressure or heart disease
• Nausea severe enough to be worse than whatever it was meant to help with
• New or worsening darkening of the skin, gums, or freckles with repeated use, a melanocortin-pathway effect shared with Melanotan II

Stacking

There's no widely established stacking convention for PT-141, and that's worth stating plainly rather than manufacturing one. Because it's used as-needed rather than as part of a sustained course, most people run it on its own rather than layering it into a weekly protocol built around a different compound.

Combination to approach carefully: Melanotan II. Since PT-141 is a refined metabolite of Melanotan II working through the same receptor family, combining the two stacks effects on the identical pathway rather than adding something new, and it's reasonable to expect the nausea, flushing, and blood pressure effects each carries individually to compound rather than cancel out. We found no source establishing a safe or studied combined protocol.

Expected results timeline

Same session: onset is reported within roughly 45 minutes to a few hours of dosing, which is the entire point of an on-demand compound rather than a maintained one.

Across repeated use: the RECONNECT trials measured outcomes over 24 weeks of on-demand use, so the desire and satisfaction improvements reported in the trial data reflect a pattern of repeated, as-needed dosing over months, not a single use.

Extended, continued use: the RECONNECT extension study followed participants for 52 weeks and found the efficacy signal held with a consistent side effect profile, which is a longer continuous safety window than most compounds on this site have behind them.

What to expect realistically: a 2024 reanalysis of the trial data found the effect sizes, while statistically significant, were modest relative to placebo, and that how meaningful the FDA's chosen outcome measures actually are remains debated in the research literature. Nausea, reported by roughly 40% of trial participants, was the most common reason people who discontinued gave for stopping, more often than lack of effect.

Administration technique

1. The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target amount.
2. The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
3. The calculated volume is drawn into an insulin syringe or similar fine-gauge syringe.
4. A subcutaneous site is chosen, commonly the abdomen or the front of the thigh.
5. The skin is pinched and the injection given at roughly a 45-degree angle, held for a few seconds before withdrawal.
6. Timing is what matters most to log here, roughly 45 minutes before the activity it's meant for, along with the amount used and how it was tolerated, since the whole point is dialing in what works for a given person.

Side effects and safety

Common: nausea is the most frequently reported effect, at roughly 40% of participants in the pivotal trials, and it tends to climb with amount. Flushing and headache follow behind it.

Less common: a transient rise in blood pressure and a corresponding drop in heart rate have been reported in the hours following a dose, which is why the labeled use isn't recommended for anyone with uncontrolled high blood pressure or known cardiovascular disease. Darkening of the skin, gums, or existing freckles has been reported with repeated melanocortin-pathway use, more prominently associated with Melanotan II but sharing the same mechanism.

Stopping due to side effects: nausea was the most common reason trial participants who discontinued gave, ahead of lack of effect, according to the RECONNECT exit survey data.

What we don't know: the approval and the trial data apply specifically to premenopausal women with generalized, acquired hypoactive sexual desire disorder; it hasn't been approved for men or for postmenopausal women, and the evidence base outside that studied population is thin. Long-run outcomes in people using research-grade material outside clinical supervision aren't tracked anywhere.

Contraindications: uncontrolled high blood pressure and known cardiovascular disease are the two most consistently cited, given the transient blood pressure effect. Pregnancy, breastfeeding, and use in minors all have no research-grade safety data behind them and should be avoided.

Drug interactions: naltrexone is specifically flagged in the approved product's labeling as reducing bremelanotide's effect, since it works through an opioid-antagonist mechanism that overlaps with part of PT-141's own pathway. Anyone taking naltrexone for another reason should know the two aren't expected to work well together.

PT-141 vs. Melanotan II

If you're weighing PT-141 against something else, Melanotan II is the compound people actually cross-shop it against, since it's the parent compound PT-141 was refined from and the two get confused for each other constantly.

Choose PT-141 if: the desire pathway specifically is what you're researching, and having an actual FDA-approved evidence base behind the compound matters to you.

Choose Melanotan II if: the pigmentation effect is the actual interest, understanding that the approval-track evidence PT-141 has doesn't carry over to it.

See the Melanotan II research notes for its own mechanism and pricing.

Storage and handling

Lyophilized powder: refrigerate at 2 to 8°C, and protect from light. Properly stored, the unreconstituted powder is commonly described as stable for 12 to 24 months.

Reconstituted solution: refrigerate and use promptly. Because PT-141 is used occasionally rather than on a fixed weekly schedule, reconstituting a smaller volume that matches how often you'll actually use it is worth planning for, rather than mixing a large batch that sits unused.

Signs of degradation:

• Cloudiness or visible particles in a solution that was previously clear
• Discoloration of the powder or reconstituted liquid
• A previously reliable effect that unexpectedly stops showing up at an unchanged amount, though this is a soft signal at best

FAQ

PT-141 or Melanotan II, which one do I actually want? If the desire pathway and an actual FDA approval behind it matter most, PT-141. If the pigmentation effect is the real interest, Melanotan II, understanding it has no approval-track evidence behind it.

How is it typically dosed? Most commonly 1 to 2 mg, taken roughly 45 minutes before the activity it's meant for, mirroring the RECONNECT trial protocol.

How often can it be used? The approved label caps use at one dose in 24 hours and no more than 8 doses in a month, a ceiling commonly referenced as a reasonable upper bound.

Does it need to build up over time like other compounds? No. It's an on-demand compound, not a course that escalates toward a maintenance amount.

Is it safe to combine with Melanotan II? No studied combination protocol exists, and the two work through overlapping receptors, so side effects are reasonable to expect to compound rather than cancel out.

Is there a blood pressure risk? Yes, a transient rise in blood pressure has been reported after dosing, which is why it isn't recommended for anyone with uncontrolled high blood pressure or known cardiovascular disease.

Does naltrexone interact with it? Yes, the approved labeling specifically flags naltrexone as reducing bremelanotide's effect.

How is it stored? Refrigerated as a powder, refrigerated and used promptly once reconstituted, ideally in smaller batches matched to how often it's actually used.

Bottom line

Key dosing takeaways:

• 1 to 2 mg, taken roughly 45 minutes before the activity it's for, is the pattern most closely mirroring the trial data behind the approval
• This is an on-demand compound, not a weekly course, so titration schedules and maintenance amounts, the center of gravity for most guides on this site, don't apply here
• Nausea is the side effect most likely to actually change how someone uses it, and it's the most common reason trial participants who stopped gave

Best practices:

• Reconstituting a smaller volume matched to realistic frequency of use avoids letting solution sit unused past its stability window
• Logging the amount, timing, and how it was tolerated helps dial in what actually works, since individual response varies more here than with a fixed weekly schedule
• Knowing the naltrexone interaction and the blood pressure caution matters more here than for most compounds on this site, since this one is genuinely FDA-reviewed and both are in the label

Works best for people who:

• Want a compound with an actual FDA-approved evidence base behind the specific use they're researching
• Are looking for an as-needed option rather than a sustained daily or weekly course
• Can tolerate, or are prepared to manage, dose-dependent nausea and a transient rise in blood pressure